Background Bartter patients may be hypercalciuric. Additional abnormalities in the metabolism of calcium, phosphate, and calciotropic hormones have occasionally been reported. 
Introduction
Bartter syndrome is a group of very similar recessive tubulopathies with a unifying pathophysiology consisting of postproximal salt loss [1] . Affected patients present with normal or low blood pressure, hypokalemia, hyperreninemia, and a tendency towards nephrocalcinosis and hypercalciuria in the neonatal variant [1] . Further abnormalities in the metabolism of calcium, inorganic phosphate, and calciotropic hormones have sometimes been noted in these disorders, although data characterizing the levels of classic calciotropic hormones during the stable phases of the condition are sparse [2, 3] .
Here we present the results of our study in which we investigated the metabolism of calcium, inorganic phosphate, and classic calciotropic hormones in patients affected with Bartter syndrome.
Patients and methods
Participants eligible for entry into the study were all Bartter patients on regular follow-up at the renal unit of the Division of Pediatrics, San Leopoldo Mandic Hospital, Merate (Italy). Fifteen patients from 14 different families (8 females and 7 males, median age 7.3 years, age range 3.2-18) who presented for a scheduled visit between September and November 2012 were ultimately enrolled in the study. These patients had a history of polyhydramnios (N=13), premature birth (N=13), or ultrasound findings consistent with nephrocalcinosis (N=13) ( Table 1) . A control group of 15 healthy subjects (8 females and 7 males median age 11 years, age range 6.9-18 years) was also studied.
The study design was approved by the Human Subjects Research Committee of Merate-Lecco Hospital.
The diagnosis of Bartter syndrome was based on the presence of normal or low blood pressure, hypokalemia, inappropriately high urinary excretion of chloride, and hyperreninemia. A molecular evaluation of the SLC12A1, KCNJ1, CLCNKB, and BSND genes had been performed on the 15 patients, according to standard procedure [4, 5] . The Bartter patients, who did not discontinue their respective medication with potassium chloride (N=15), the inhibitor of prostaglandin synthesis indomethacin (N=14), and the potassium-sparing diuretic spironolactone (N=3), and the control subjects attended the outpatient clinic after overnight fasting and received a tap water load of 400 mL [6] . After voiding the bladder, an approximately 2-h urine specimen was collected and a mid-point blood sample was collected [6] . Creatinine, sodium, chloride, potassium, total calcium and magnesium, and inorganic phosphate were assessed in both the blood and urine; urea, bicarbonate, albumin, 25-hydroxyvitamin D, alkaline phosphatase, intact parathyroid hormone (PTH), and osteocalcin were assessed in the blood only. Creatinine, urea, sodium, bicarbonate, chloride, potassium, albumin, total calcium and magnesium, and inorganic phosphate were measured on an automated auto-analyzer using colorimetric assays or ion-selective electrodes. Intact PTH was measured by a two-site radioimmunometric assay, 25-hydroxyvitamin D was measured using a competitive protein-binding assay, and osteocalcin was measured by radioimmunoassay, as previously reported [6] . The glomerular filtration rate (GFR) was estimated from height measurements and plasma creatinine levels [7] . Standard equations were used to calculate the fractional urinary excretion of sodium, chloride, potassium, calcium, magnesium, and inorganic phosphate and the maximal tubular reabsorption of inorganic phosphate, which is the best means of defining the renal tubular handling of this ion [8, 9] . Albumincorrected plasma calcium was calculated as follows: for every gram/liter by which plasma albumin exceeds 40 g/L, 0.025 is subtracted from the total calcium measurement, with the reverse procedure for albumin values of <40 g/L. Blood and urinary levels of sodium, chloride, potassium, and magnesium are age-and gender-independent [10] , but blood levels of inorganic phosphate and those of its maximal tubular reabsorption vary significantly with age and gender [8, 9] . Hence, the values obtained in our study were also compared with those given in the literature [8, 9] and expressed as the standard deviation score (SDS). Descriptive statistics are presented as the median and interquartile range (25th to 75th percentile and includes half of the data points). Two-tailed Wilcoxon-Mann-Whitney tests for independent samples and linear regressions with the rank correlation coefficient r s were performed for the analysis. Significance was assumed when P<0.05.
Results

Molecular biology
Genetic analysis revealed mutations in 12 of the 15 patients enrolled in the study, with three patients having a homozygous mutation, eight having a compound heterozygous mutation, and one having a single heterozygous mutation ( Table 1) . One of these patients has been previously diagnosed as Bartter syndrome type IV based on the presence of a sensorineural hearing loss [11] . Ten mutations had been previously described, whereas seven mutations (4 missense and 1 frameshift in the SLC12A1 gene and 1 missense and 1 frameshift in the CLCNKB gene) are novel. All of the new variants were considered to be pathogenetic-the two frameshift mutations because they lead to truncated protein synthesis, and the missense mutations because all are on conserved residues and were not detected in 100 healthy chromosomes or found in the Exome Variant Server database. Molecular analysis did not detect any mutation in three patients. Clinical and biochemical data Growth and laboratory findings are shown in Table 2 and Fig. 1 . Body height, height SDS, weight and weight SDS were significantly lower in the group of patients affected with Bartter syndrome than in the control group. Patients affected with Bartter syndrome and control subjects did not significantly differ with respect to puberty stage, plasma creatinine and urea, estimated GFR, plasma bicarbonate and chloride, and plasma and urinary sodium and magnesium. As expected, hypokalemia, hyperkaliuria, hyperchloriduria, and hypercalciuria were noted in Bartter patients. Plasma inorganic phosphate level (P<0.01) and maximal tubular phosphate reabsorption were significantly reduced (P<0.01) and serum intact PTH level significantly increased (P<0.01) in Bartter patients as compared with control subjects. However, patients and controls did not significantly differ with respect to total calcium blood level, serum 25-hydroxyvitamin D, plasma alkaline phosphatase and serum osteocalcin. PTH level was >10 pmol/L in three patients, with only one of these three patients having a mildly reduced GFR of 58 mL/(min.1.73 m 2 ). Figure 2 shows the relationship between the maximal tubular reabsorption of phosphate and its plasma level in Bartter patients and healthy controls, which are compared with age-and sex-specific reference values from the literature [4, 5] . The maximal tubular reabsorption of phosphate was low in three patients, and circulating phosphate level was low in one patient.
In Bartter patients we noted a significant inverse correlation (P<0.05) between total plasma calcium or GFR, taken as the independent value, and PTH, taken as the dependent value (Table 3) . Finally, a significant positive correlation was noted between PTH and osteocalcin (P<0.005) and between urinary chloride or sodium and urinary phosphate (P<0.001). On the contrary, no significant correlation was noted between urinary calcium and PTH, between urinary or circulating phosphate and PTH, and between maximal tubular reabsorption of phosphate and PTH.
Discussion
The clinical and laboratory characteristics of Bartter syndrome may be mimicked among others by treatment with loop diuretics [1] . These natriuretic agents directly increase urinary phosphate excretion in the presence of a normal extracellular fluid volume [12] . On the other hand, there is no phosphaturia in the presence of a contracted extracellular fluid volume, i.e., when urinary salt losses are not replaced [12] . Our casecontrol study was performed in biochemically and genetically characterized Bartter patients. In these unselected patients, who were on long-term management with potassium chloride, indomethacin and, more rarely, spironolactone, we determined hypercalciuria, renal phosphate wasting, and elevated circulating PTH levels.
The molecular biology studies performed in our patients also disclosed seven previously unreported mutations in either the SLC12A1 or CLCNKB genes.
To our knowledge, the metabolism of calcium, inorganic phosphate, and PTH in Bartter patients has only been addressed in our study and in two earlier studies [2, 3] , although the latter two studies did not include a well-defined pediatric control group (Table 4) . The tendency towards elevated PTH levels and hyperphosphatemia noted in German patients in the study of Leonhardt et al. [2] is likely the consequence of a mildly reduced GFR. As in our patients, a tendency towards hypophosphatemia was noted in Spanish pediatric patients, reported by Rodríguez-Soriano et al. [3] , with a normal GFR (phosphaturia was not measured in these patients). However, contrary to our patients, in the Spanish patients, the PTH level was normal and the circulating calcium level was slightly elevated. As in our patients, hypophosphatemia and hyperparathyroidism were also noted in an adolescent case of Bartter syndrome reported 35 years ago [13] . The mechanisms underlying renal phosphate wasting and hypophosphatemia in Bartter patients remain elusive. Bartter patients tend to be alkalotic; it is recognized, however, that metabolic alkalosis, contrary to respiratory alkalosis, does not noticeably modify phosphate metabolism [14] [15] [16] . There is some phosphate wasting in primary hyperparathyroidism, but no correlation was noted between urinary or circulating phosphate and PTH in our Bartter patients [17] . Prostaglandin overproduction, a constant finding in Bartter syndrome, might underlie hyperphosphaturia in our patients [14] [15] [16] . This assumption is supported by the observation that circulating phosphate levels increase in patients with Barter syndromes who are being treated with inhibitors of prostaglandin synthesis [2] . When we take into account that our Bartter patients were on treatment with indomethacin, an effective inhibitor of prostaglandin synthesis, we can assume that factors other than hyperprostaglandinism mainly account for renal phosphate wasting. We feel that the mild tendency to renal phosphate wasting observed in our Bartter patients results from a phosphaturic effect associated with the renal tubular dysfunction, which is in part counterbalanced by existing extracellular fluid volume contraction [12] . This impression is supported by the significant correlation between urinary chloride or sodium and urinary phosphate.
There are a number of limitations to our study. First, we included Bartter patients with both prenatal and classic presentation. Second, only a few patients (N = 15) were studied. Third, we did not measure urinary prostaglandin excretion and phosphaturic hormone fibroblast growth factor level [15] .
In conclusion, this case-control study demonstrates the existence of a tendency towards elevated circulating PTH levels and renal phosphate wasting in Bartter patients with normal GFR. A multicenter study with a large number of patients and the determination of prostaglandinuria, reninemia, fibroblast growth factor 23, and 1,25-dihydroxyvitamin D should be helpful in establishing the mechanisms underlying these biochemical abnormalities.
